1 September 2016
Dr Cath Mummery, head of clinical trials at the Dementia Research Centre, UCL Institute of Neurology, was interviewed on BBC News and Channel 4 yesterday evening about the interim results of a Phase I study of adecanumab, a monoclonal antibody, reported in Nature.
Dr Mummery was not involved in the Phase I study but is now the Principal Investigator for the Phase III study being done at UCL Institute of Neurology on the back of these results. The sponsor is Biogen.
The study found a marked reduction in amyloid load using PET scans and confirmed the drug removes amyloid from brains of people with Alzheimer's disease (AD).